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Abstract Hairy cell leukaemia (HCL) is a rare haematologi-
cal malignancy, with approximately 175 new incident cases in
France. Diagnosis is based on a careful examination of the
blood smear and immunophenotyping of the tumour cells,
with a panel of four markers being used specifically to screen
for hairy cells (CD11c, CD25, CD103 and CD123). In 2011,
the V600E mutation of the BRAF gene in exon 15 was
identified in HCL; being present in HCL, it is absent in the
variant form of HCL (HCL-v) and in splenic red pulp lym-
phoma (SRPL), two entities related to HCL. The management
of patients with HCL has changed in recent years. A poorer
response to purine nucleoside analogues (PNAs) is observed
in patients with more marked leukocytosis, bulky splenomeg-
aly, an unmutated immunoglobulin variable heavy chain
(IgVH) gene profile, use of VH4–34 or with TP53 mutations.
We present the recommendations of a group of 11 experts
belonging to a number of French hospitals. This group met in
November 2013 to examine the criteria for managing patients
with HCL. The ideas and proposals of the group are based on
a critical analysis of the recommendations already published
in the literature and on an analysis of the practices of clinical
haematology departments with experience in managing these
patients. The first-line treatment uses purine analogues:
cladribine or pentostatin. The role of BRAF inhibitors,
whether or not combined with MEK inhibitors, is
discussed. The panel of French experts proposed recom-
mendations to manage patients with HCL, which can be
used in a daily practice.
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Background
The epidemiological data relating to hairy cell leukaemia
(HCL) are limited. HCL is a rare haematological malignancy,
representing 2 % of all leukaemia [1]. Between 1992 and
2000, a review of 12 American databases covering 14 % of
the American population revealed a higher frequency of HCL
among white Americans than among African Americans or
Asians [2]. The data from the lower Normandy Regional
Register of Haematological Malignancies indicate an inci-
dence standardized to the world population of 0.29±0.08 per
100,000. The incidence is higher in men (0.50±0.15) than in
women (0.12±0.008) [3]. These data, extrapolated to France,
suggest approximately 175 incident cases of HCL per year.
The median age of patients at diagnosis is 52 (24–81). The
SEER (Surveillance, Epidemiology and End Results Program;
http://seer.cancer.gov) study conducted in 3,776 patients
shows an improvement in survival over the calendar periods
analysed (before 1984, 1984–1990, 1991–1999 and 2000–
2008) and a reduction in the risk of mortality of 6.5 % per
year. The survival rate for HCL is lower among African
Americans [4].
The causes of HCL remain unknown. The existence of
familial forms suggests a genetic predisposition in some cases
[1]. The role of certain environmental factors remains unclear;
a risk associated with forage growing or exposure to organo-
phosphate insecticides has been identified, as has a tobacco-
associated protective effect [5]. In 2011, mutations were iden-
tified in five genes (BRAF, CSMD3, SLC5A1, CNTN6 and
OR8J) by means of whole-exome high-throughput sequenc-
ing performed on the (>90 %) CD19+ tumour cells from a
patient with HCL and on the (>98 %) CD19− mononuclear
cells from the same patient at the time of remission [6]. The
V600E mutation of the BRAF gene in exon 15 was confirmed
by means of direct sequencing in 47 other patients with HCL.
However, it was absent in 195 patients with another chronic B
cell lymphoproliferative disorder, including patients with mar-
ginal zone lymphoma.
HCL may be associated with other haematological malig-
nancies, particularly multiple myeloma (MM), large granular
lymphocytic leukaemia (LGL) or chronic myeloid leukaemia
(CML) [7].
Diagnosis
The circumstances under which the disease is discovered are
related to the consequences of bone marrow suppression,
including severe or recurrent infections, to the detection of
splenomegaly, whether symptomatic or not, or to the often
fortuitous identification of hairy cells during a routine blood
count.
In all cases, the diagnosis is based on a careful examination
of the blood smear and immunophenotyping of the tumour
cells.
Identification of hairy cells in the blood smear
Hairy cells—large cells with abundant, poorly demarcated,
grey to weakly and irregularly basophilic cytoplasm—display
fine cytoplasmic projections distributed around the entire
circumference of the cell. “Granular/lamellar” cytoplasmic
inclusions with the appearance of slightly basophilic rods with
a clear central area are detected occasionally. The nucleus-to-
cytoplasm ratio is low, and the nucleus is often in an eccentric
position. Oval or round, it can sometimes be kidney-shaped.
The nuclear chromatin has a dispersed appearance and never
coarse, and the nucleolus, which is not readily seen, is small
and often solitary. Sometimes difficult to identify in a poor
quality smear, the cells are found consistently in the blood
smear, even if only in small numbers.
Monocytopenia is almost always present. It may be erro-
neously absent from the results yielded by automated
haematology analysers, which regularly identify hairy cells
as monocytes. There is no lymphocytosis. Neutropenia, anae-
mia that is often mildly macrocytic and thrombocytopenia of
varying severity often complete the constellation of laboratory
findings.
Immunophenotype
Immunophenotyping can be performed on blood or bone
marrow. Hairy cells must be looked for within a large cell
gate (in the vicinity of the monocyte gate).
It comprises an analysis of the B cell lineage markers
(CD19, CD20) combined with a panel of markers used spe-
cifically to screen for hairy cells (CD11c, CD25, CD103,
CD123) and screening for an immunoglobulin light chain
isotype restriction.
The four markers CD11c, CD25, CD103 and CD123 de-
fine the HCL score [8], which distinguishes HCL from other B
cell haematological disorders associated with hairy cells, in-
cluding the variant form of HCL (HCL-v), splenic marginal
zone lymphoma (SMZL) and splenic red pulp lymphoma
(SRPL). One point is given to each marker when it is
expressed, and no point is given when it is not expressed. A
score of 3 or 4 is observed in 98 % of cases of HCL, unlike
with other B cell haematological disorders associated with
hairy cells, where the score is usually 0 or 1. It is not compul-
sory to calculate this score, the co-expression of the markers
CD11c, CD25 and CD103 representing a sufficient basis on
which to diagnose HCL. If a negative result is obtained for one
of these three markers, there is a need to assess the expression
of CD123 and to calculate this score.
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Although there is no need to calculate it for the diagnosis of
HCL, the Royal Marsden Hospital (RMH) score [9] used in
chronic lymphocytic leukaemia (CLL) is usually 0 or 1.
Bone marrow examination
This is not obligatory, except in clinical trials.
Where diagnosis proves difficult or immunophenotyping is
inconclusive and the number of hairy cells present is small, a
bone marrow biopsy combined with bone marrow aspiration is
desirable. Hairy cells, cells which are easily recognizable by their
oval or kidney-shaped nuclei, their chromatin pattern, the clear
“halo” which separates the nuclei and the abundant cytoplasm
which is difficult to see, have a typical “fried egg” appearance.
Immunohistochemistry (IHC) is sometimes useful for de-
tecting hairy cells in limited numbers—expression of the
isoenzyme 5 of tartrate acid-resistant phosphatase (TRAP) in
the form of non-specific but characteristic granular cytoplasm
positivity, expression of CD20 and CD72 and the mutated
BRAF protein [10].
Cytogenetic and molecular analyses
Cytogenetic studies and BRAF V600E mutation testing [6,11]
are not necessary for diagnosis.BRAFV600Emutation testing
may be useful in cases of diagnostic uncertainty and in cases
where therapeutic management is complex.
Other investigations at diagnosis
Clinical evaluation must include the following:
– A patient history, looking for any familial history of
haematological malignancy or autoimmune disorders;
– Identification of any systemic symptoms;
– Checking for signs of disease, especially checking for
splenomegaly. The use of imaging can be helpful for this.
Ultrasonography of the spleen can be used to measure the
size of the spleen and to identify abdominal lymphade-
nopathy, which is uncommon.
Biological tests include the following:
– A complete blood count with differential including a
reticulocyte count;
– Serum protein electrophoresis to look for a monoclonal
component;
– Haemolysis screen in the presence of suspicion.
The following is desirable:
– Preservation of tumour material in blood and/or bone
marrow before any treatment.
Differential diagnosis
The variant form of HCL and SRPL constitutes forms which
are difficult to diagnose with areas of overlap with HCL [12].
Variant form of HCL
Despite being described as long ago as 1980 [13], the variant
form of HCL (HCL-v) is a rare entity (10 % of all cases of
HCL). The terminology is ambiguous, because it is a disorder
distinct from HCL. It affects men, with a median age of
71 years (48–92 years) [14,15]. Monocytopenia is absent,
and leukocytosis is >10×109/L in more than 90 % of cases.
Examination of the blood smear shows a proliferation of hairy
cells (20–95 % of the lymphoid cells) of medium to large size
with a large and clearly visible nucleolus and condensed
chromatin. There is infiltration of the splenic red pulp. The
HCL score is low (0, 1 or 2) with a strong expression of
CD11c (87 %) and CD103 (60 %) contrasting with a weak,
rare expression of CD123 (7 %) or CD25 (6 %) [15,16]. The
BRAF V600E mutation is absent.
Splenic red pulp lymphoma or SRPL
SRPL is rare [17] and was described recently. It affects men
(sex ratio, 1.64) with a median age of 77 years (46–91). In
three quarters of cases, lymphocytosis is present and exami-
nation of the blood smear shows the presence of a proliferation
of hairy cells (median, 60 %; 26–91 % of the lymphoid cells)
of small to medium size with, in the majority of cells, a small
or invisible nucleolus. The cellular phenotype is very hetero-
geneous, quite close to HCL-v, with a strong expression of
CD11c (97 %), a variable expression of CD103 (38 %) and
little or no expression of CD123 (16 %) and CD25 (3 %). The
blood karyotype may show anomalies such as 7q deletion.
The immunoglobulin variable heavy chain (IgVH) gene pro-
file is mutated in 80 % of cases, with over-represented use of
VH3–26 and VH4–34. The BRAF V600E mutation is absent
in SRPL.
Required pretreatment evaluation
Assessment of prognostic factors
Unless there is a therapeutic indication, there is no justification
for carrying out any additional investigations for the assess-
ment of prognostic factors. No prognostic factor will modify
the choice of first-line treatment, which is based on purine
nucleoside analogues (PNAs): cladribine or pentostatin.
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Studies in patients treated with cladribine have resulted in
the identification of factors, which may reduce the following
responses to treatment:
– Leukocytosis >10×109/L [18]
– Bulky spleen extending >10 cm below costal margin [18]
– Unmutated IgVH gene profile ≥98 % [18]
– Use of the VH4–34 repertoire [19]
– Mutation of the TP53 gene [18].
Other factors reduce event-free survival (EFS) [18] as
follows:
– Bulky spleen extending >10 cm below costal margin
– Elevated levels of circulating hairy cells >10×109/L
– Unmutated IgVH profile.
TP53 mutation testing and analysis of the IgVH gene
repertoire to test for VH4–34 positivity must be performed
in the event of a relapse, before the second line of treatment,
on previously frozen material or fresh material if possible.
Pretreatment assessment
Parameters considered necessary for a complete pretreatment
evaluation may differ depending on whether or not the patient
is treated in a clinical protocol.
The following are essential pretreatment tests (clinical trials
and general practice):
– Physical examination including the determination of the
performance status as defined by the Eastern Cooperative
Oncology Group (ECOG) and the identification of co-
morbidities and potential sites of infection.
– Serum chemistry including creatinine with calculation of
creatinine clearance (Modification of Diet in Renal Dis-
ease (MDRD) Study), haemolysis screen (direct antiglob-
ulin test, haptoglobin, unconjugated bilirubin and lactic
dehydrogenase) and liver function tests (transaminases)
with hepatitis B and C serology (risk of reactivation after
immunosuppressive therapy).
– Preservation of cells and serum in a tumour bank is
recommended.
– Chest radiograph and abdominal and pelvic imaging.
The following are additional pretreatment tests that may be
performed in clinical trials:
– Blood and bone marrow karyotypes analysis.
– BRAF V600E mutation testing.
– Mutational status of IgVH gene and analysis of the VH
gene usage.
– Mutational status of TP53 gene.
Treatment
Indications for treatment
Criteria for initiating treatment may vary depending on wheth-
er or not the patient is treated in a clinical trial. In general
practice, treatment is indicated in the presence of at least one
of the signs of active disease as follows:
1. Symptomatic splenomegaly
2. Cytopenia (involving at least one cell type)
(a) Haemoglobin <10 g/dL
(b) Platelets <100×109/L
(c) Neutrophils <1×109/L
3. Recurrent or severe infections
In the absence of treatment, clinical monitoring and mon-
itoring of the blood count are necessary every 3 months for the
first year and then every 6 months.
Treatment strategy
Inclusion in a prospective study protocol is recommended. In
general practice, the recommendations are as follows.
First-line treatment
The first-line treatment is based on PNAs [20–22]: cladribine
or pentostatin. The different dosing regimens for the two
medicinal products are listed in Table 1.
There are no data in the literature proving the superiority of
one drug over the other. The choice between pentostatin and
cladribine is based essentially on the presence or absence of
renal impairment, the severity of the cytopenias and the dosing
regimens of the products. Cladribine may be used intrave-
nously (IV) or subcutaneously (SC), unlike pentostatin, which
is used only via the IV route. The SC form offers ease of
administration and the option of treatment on an outpatient
basis, unlike cladribine IV.
In the presence of renal impairment (plasma creatinine
clearance (MDRD) <60 mL/min), pentostatin is contraindi-
cated owing to limited experience, unlike cladribine.
Special cases
In cases of severe neutropenia (neutrophil count <0.2×109/L)
and/or uncontrolled active infection, the treatment of choice is
interferon via the SC route at a dose of 3 million units×3 per
week followed by a purine analogue once the neutropenia has
been corrected. Another option, although not validated in this
indication, is the use of rituximab on its own at a dose of
375 mg/m2 IV for 4 weeks in the place of interferon.
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In cases of active haemolytic anaemia, consideration might
be given to rituximab.
In cases of pregnancy, the only treatment that can be used is
interferon via the SC route at a dose of 3 million units×3 per
week.
In cases of two co-existing haematological disorders or a
concomitant haematological disorder, the management ap-
proach should be discussed at a multidisciplinary meeting.
Relapses
Only symptomatic relapses require treatment.
First relapse In cases of late relapse (>60months), PNAsmay
be used again. No recommendations exist regarding whether
or not the PNAs should be changed.
In cases of intermediate relapse (24–60 months), the
second-line treatment also relies on PNAs, whether or not a
different PNA is used and whether or not it is combined with
rituximab, administered concomitantly or sequentially (non-
validated treatment regimens) [23,24].
In cases of early relapse (<24 months), the diagnosis of
HCL must be confirmed and BRAF V600E mutation testing
must be performed.
1. If the diagnosis of HCL is confirmed, the management
approach will depend on the presence or absence of a
TP53 gene mutation and VH4–34 use.
(a) In the absence of the TP53 gene mutation, with a VH
repertoire other than VH4–34, the use of a PNA
combined with rituximab is recommended.
(b) In cases of TP53 gene mutation [25] and/or use of
VH4–34, the different treatment options are as follows:
– Immunotoxins, but they are not available in France
[26,27].
– BRAF inhibitors either alone or in combination with
MEK inhibitors. No treatment regimen is defined at pres-
ent [28–31]. The use of these treatments must take into
account the toxicity of these drugs, including their cuta-
neous effects [30,32,33].
– Bendamustine and rituximab in combination [34].
– If access to innovative compounds is impossible, a com-
bination of treatment with PNA and rituximab is
recommended.
2. If the diagnosis of HCL is not confirmed and in the
absence of a BRAF V600E mutation, an analysis of the
IgVH repertoire to test for VH4–34 use must be per-
formed. Treatment must be considered on a case-by-case
basis.
Subsequent relapses Some options used before the era of
PNAs should not be ruled out, including splenectomy and
interferon.
Prevention of infectious complications
The prevention of infectious complications occurring during
the course of HCL treatment or in the post-treatment period is
of prime importance.
In the prevention of Pneumocystis jiroveci-induced in-
fections with Bactrim® until recovery of T cell numbers to
CD4>200/mm3, there is an increased risk of allergic skin
reactions during concomitant use of Bactrim® with purine
analogues. This risk can be reduced by starting Bactrim®
1 week after the purine analogue. In cases of allergy to
Bactrim® or cytopenias potentially linked to Bactrim®,
Pentacarinat® or atovaquone (Wellvone®) aerosols may be
used.
Prevention of zoster infections with aciclovir or
valaciclovir should also be started 1 week after PNAs. The
optimal duration of prophylaxis has not been determined.
Table 1 Different dosing regimens
Dosing regimen for cladribine (2-chlorodeoxyadenosine (2-CDA))
Authorized dosages
0.14 mg/kg/day SC for 5 days
0.1 mg/kg/day as a continuous IV infusion for 7 days
Other dosages (off-label)
0.14 mg/kg/day as an IV infusion over 2 h for 5 days
0.14 mg/kg/day IVonce weekly for 6 weeks
0.14 mg/kg/day SC once weekly for 5 weeks
The dosage must be repeated in the absence of CR at 6 months
Dosing regimen for pentostatin in HCL (2′-deoxycoformycin (2′-DCF))
4 mg/m2 every 2 weeks until a maximal response is achieved, plus one
or two additional injections
Determine the creatinine clearance before each administration and
avoid the medicinal product in the presence of clearance <60 mL/
min
Dosing regimen for rituximab (4–8 doses in total)
375 mg/m2 IVonce weekly administered simultaneously or
sequentially with the purine analogue in patients without CR after a
single treatment with pentostatin or cladribine
Interferon alpha (IFN-α)
3×106 U SC daily until a maximal response is achieved and
continuation at the same dose three times weekly. In very cytopenic
patients, start on a dose of 3×106 U 3 times weekly
Splenectomy
Indicated in cases of bulky splenomegaly (>10 cm below the costal
margin) and in cases of moderate bone marrow involvement, after
immunization programme
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Growth factors should be considered on a case-by-case
basis.
No data in the literature provide a basis for either
recommending or not recommending the irradiation of labile
blood products after treatment with purine analogues.
Response criteria and evaluation
The following definitive response should be assessed:
– For pentostatin, at the end of treatment, after 8 to
10 cycles
– For cladribine, 3 to 6 months after the end of treatment.
Complete remission (CR) is defined as follows:
– Recovery of blood counts with haemoglobin >12 g/dL,
platelets >150×109/L, neutrophils >1.5×109/L and ab-
sence of circulating hairy cells
– Regression of splenomegaly
– Absence of hairy cells on the bone marrow biopsy spec-
imen, including IHC analyses (CD20, CD72).
In the absence of a bone marrow biopsy specimen, a very
good response (VGR) is defined as recovery of the blood
counts (haemoglobin >12 g/dL, platelets >150×109/L, neu-
trophils >1.5×109/L and absence of circulating hairy cells)
and regression of splenomegaly.
A partial response (PR) is defined as a poorer quality
haematological response, with persistence of splenomegaly,
cytopenias or presence of circulating hairy cells on blood
smear analysis.
In cases of PR, the treatment approach depends on the
desired objective.
If quality of life is a priority (elderly subject, comorbidi-
ties), regular haematological monitoring (clinical examination
and complete blood count) every 6 months should be
recommended.
If response quality is sought (young subject), achieving
complete remission (CR) is desirable. CR should be defined
as a negative bone marrow biopsy, including IHC, and ideally
minimal residual disease (MRD) which is undetectable in the
blood and/or bone marrow by means of flow cytometry. The
impact of detectable MRD on the risks of relapse and on
prognosis remains unknown, however [35,36]. In the absence
of CR, a new treatment, either with the same PNA or with a
combination of cladribine and rituximab, is recommended.
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